Turn this list into pipeline.
Biotech Companies in Liverpool: 29 Active Firms (2026)
Biotech companies in Liverpool develop biology-led therapies, diagnostics and research tools within the city's life-sciences base.
Buying centres tend to sit with translational research teams, clinical-development groups, laboratory directors and regulatory affairs, rather than with a single technology budget holder. Liverpool suppliers usually sell into pharmaceutical, healthcare, academic, contract-research and public-sector organisations, with engagement models ranging from collaborative research agreements and grant-backed partnerships to licence, assay-development and specialist-service contracts. Buyer behaviour is evidence-led: procurement is shaped by reproducibility, quality systems, ethics approval, consent processes and defensible intellectual property. Sales cycles therefore appear more akin to life-sciences partnerships than conventional software procurement, with technical validation often preceding any commercial commitment.
Read more
Liverpool has 29 actively trading biotech companies in this cohort, making the local market a specialist city cluster rather than a broad national pool. Reported headcount totals 388 people, so the employment footprint is visible but concentrated; many businesses are likely to remain research-led operators rather than full commercial manufacturing platforms. The presence of a small number above the £5M turnover threshold suggests some progression beyond laboratory services or grant-funded research, while newer incorporations point to continued company formation around translational science, diagnostics and research tools. For researchers, the useful read is less about volume and more about which firms have crossed from laboratory validation into repeatable external revenue.
Biotech activity in Liverpool sits inside the UK life-sciences regulatory framework, with the MHRA responsible for clinical trial approvals, treatment evaluations, marketing authorisations and pharmacovigilance where medicines are involved. Clinical work also has to align with Good Clinical Practice, ethics review and informed-consent requirements, which affects both therapeutic developers and diagnostics businesses handling human samples or clinical evidence. Market access is not only a regulatory question: approved products may still face health-technology assessment before routine public-sector use. Sector representation sits across the BioIndustry Association for biotech and the ABPI for research-based pharmaceutical activity, giving the market a policy channel as well as a compliance burden.
Liverpool’s biotech pipeline appears likely to remain shaped by early-commercial companies with specialised laboratory capability, rather than by a dense base of scaled manufacturers. That tends to favour collaboration with academic, healthcare, contract-research and larger pharmaceutical buyers, with acquisition, licensing or co-development often more plausible than standalone sales expansion. Regulatory evidence requirements will keep raising the cost of moving from discovery into clinical or translational use, especially for firms handling human samples, safety monitoring or claims linked to patient outcomes. The sector may therefore look uneven: technically credible niches, a limited scale-up layer, and periodic consolidation where external buyers want validated science.
29
Active firms
2026
5
Above £5M turnover
Larger Liverpool operators
6
Incorporated since 2022
Recent formations
Key facts
About 17% of the trading cohort reports turnover above £5M (5 of 29 firms) — the rest sits below that revenue band.
20% of the cohort was incorporated since 2022 (6 firms), so a sizeable share is in its first few filing cycles.
The MHRA approves clinical trial applications, assesses marketing authorisations or drug licences, and monitors post-authorisation safety through pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements before therapies can move through human testing.
The Office for Life Sciences estimated that the UK life-sciences industry generated £146.9 billion in turnover in 2023/2024 across 6,170 businesses and 7,320 companies.
The BIA reported that UK biotech companies raised £3.5 billion in equity investment in 2024, up 94% on the previous year and below £4.5 billion in 2021.
In 2023, the UK accounted for 11.5% of global medical-sciences citations, behind only the USA and China.
Top Liverpool Biotech companies
BIOGRAD LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides clinical trial services, biobanking, and human tissue sample collection and storage. Develops biomanufacturing capabilities for advanced cell therapies, including stem cell and CAR‑T…
Serves private and NHS hospitals, UK and international biotech and pharmaceutical companies, academic researchers, and government bodies.
Financial Health
StrongStrong · Growing, Hiring · 29% CAGR over 4y
Location
Altona Diagnostics UK Limited
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies molecular diagnostic reagents and PCR-based assays for detection of viral, bacterial, and other pathogens. Also provides automated diagnostic workflow systems, laboratory…
Serves clinical diagnostic laboratories, hospital pathology and microbiology departments, and healthcare organisations using molecular testing for infectious diseases, including respiratory,…
Financial Health
StableStable · Hiring · 6% CAGR over 3y
Location
BIOHABIT LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
West Derby Healthcare Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides microbiological testing, consultancy and contract research focused on biofilms, antimicrobial efficacy, virology and cell biology. Conducts laboratory studies and product evaluations for…
Serves B2B product developers, R&D teams and manufacturers in medical devices, wound care, oral care, cosmetics, veterinary medicine, infection control, industrial systems, and food and drink sectors.
Financial Health
StableStable · -76% CAGR over 3y
Location
PHARMARON BIOLOGICS (UK) LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsProvides contract research, development and manufacturing services for pharmaceuticals, biologics and advanced therapies. Supports drug discovery, preclinical testing, clinical development and…
Serves pharmaceutical, biotechnology, cell and gene therapy, vaccine and medical device companies seeking outsourced support from discovery through commercialization.
Financial Health
StableStable · 2% CAGR over 1y
Location
ENTERAL ACCESS TECHNOLOGIES LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures medical devices for enteral feeding tube placement. Produces the DoubleCHEK device, which combines CO2 and pH indicators to help clinicians confirm correct positioning of…
Sells to healthcare providers, particularly NHS hospitals and clinicians involved in enteral feeding, gastric decompression and naso/oro gastric tube placement for patients.
Financial Health
StableStable · 0% CAGR over 4y
Location
TROPHICELL LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
Mycardium Nominee Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsProvides artificial intelligence–based software and core lab services for analysis of cardiac MRI and echocardiography scans. Offers imaging data analysis, quality control and reporting to support…
Serves hospitals, cardiac imaging departments and healthcare providers, including NHS buyers, plus pharmaceutical, biotech and medical device sponsors running cardiovascular clinical trials.
Financial Health
StableStable · 0% CAGR over 1y
Location
INTELLIHEP LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · -10% CAGR over 4y
Location
REFOLD THERAPEUTICS LIMITED
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
Nano Biosols Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · 0% CAGR over 4y
Location
MC DIAGNOSTICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular diagnostic assays and instruments for immunogenetics, transplantation and transfusion testing. Provides HLA typing services, multiplex assay development, microarray…
Serves healthcare and laboratory organisations in the UK and Ireland, including transplant and transfusion diagnostics labs, blood banks, immunogenetics, microbiology and human genetics teams.
Financial Health
StableStable · 0% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops biotechnology technologies for purification and extraction of proteins and nucleic acids (DNA and RNA). Also designs enzyme and biocatalyst systems using directed evolution for applications…
Serves B2B life sciences customers, including research labs, clinical diagnostics teams and biopharmaceutical developers needing protein and nucleic acid purification. Also targets proteomics,…
Financial Health
WeakWeak · 0% CAGR over 2y
Location
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsConducts drug discovery research focused on developing therapeutics for oncology, fibrotic and metabolic diseases. Uses multidisciplinary approaches to identify and advance candidate compounds…
Financial Health
DistressedDistressed
Location
Livful Innovation Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops pharmaceutical and health technologies, including experimental cancer treatments and insect‑repellent products. Identifies and licenses biomedical intellectual property, conducts early‑stage…
Serves underserved populations in the Global South through local health systems, public/private health organisations and pharmaceutical partners, with out-licensing to global north pharma companies.
Financial Health
HealthyHealthy · Hiring · 9% CAGR over 4y
Location
CHEMOVATION LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Manufactures and supplies diagnostic products used in clinical, industrial and veterinary laboratories, providing testing systems and related materials that support microbiology and other…
Sells B2B to clinical laboratories, healthcare diagnostic providers, industrial testing labs and veterinary testing organisations needing diagnostic products.
Location
Ladder Therapeutics Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops RNA‑targeted therapeutics using AI‑driven drug discovery. Designs small‑molecule compounds that interact with RNA to modulate translation and splicing, enabling drug development against…
Serves biopharmaceutical companies, biotech firms and drug discovery teams with challenging RNA or hard-to-drug therapeutic targets, particularly organisations developing treatments for diseases with…
Financial Health
DistressedDistressed · -24% CAGR over 2y
Location
RIOTECH PHARMACEUTICALS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
Firstkind (Singapore) Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies non‑invasive wearable medical devices using neuromuscular electrostimulation technology. Products such as the geko device are used in hospitals for venous thromboembolism…
Sells to healthcare providers and clinical teams, including NHS trusts, hospitals, wound care centres and surgical, stroke, obstetrics and vascular disorder specialists; also engages distributor…
Financial Health
StableStable · 0% CAGR over 2y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · -63% CAGR over 5y
Location
BACHEM (U.K.) LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and manufactures peptides and oligonucleotides for pharmaceutical and biotechnology applications. Provides contract development and manufacturing services, including CMC development, GMP…
Serves pharmaceutical and biotechnology companies worldwide, including R&D, sourcing, quality, regulatory and production teams requiring peptide and oligonucleotide materials from research through…
Financial Health
WeakWeak · -1% CAGR over 2y
Location
Technical Consultancy Services Ltd.
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsManufactures microbiology consumables and sampling products, including transport and dry swabs, hygiene and environmental sampling kits, pathogen detection kits, and microorganism preservation…
Serves clinical, veterinary, food and beverage, pharmaceutical, cosmetics, environmental, educational and forensic laboratories, plus hygiene and quality teams managing microbiology sampling and…
Financial Health
StableStable · 0% CAGR over 4y
Location
Revivocell Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · Hiring · 19% CAGR over 4y
Location
INSECT RESEARCH SYSTEMS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
CERNERETEC LTD
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops medical devices and software for ultra long‑term EEG monitoring. Offers the EpiSight system with a subcutaneous EEG implant, wireless recorder, mobile app and analytics platform to collect…
Serves epilepsy-focused healthcare professionals, neurology departments and hospitals, alongside pharmaceutical and neuroscience drug developers seeking longitudinal EEG data for patient management,…
Financial Health
StrongStrong · Growing, Hiring · 41% CAGR over 2y
Location
Sky Medical Technology Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops bioelectronic wearable medical devices for clinicians that use neuromuscular electrostimulation to increase blood circulation. Products such as the geko device help prevent blood clots,…
Serves clinicians and healthcare organisations treating vascular-related conditions, including wound care, blood clot prevention, post-operative or trauma oedema management, and recovery support for…
Financial Health
StableStable · 5% CAGR over 2y
Location
Unlock all 29 leads
Showing 28 of 29 — +1 more with verified decision-maker contacts, live data, and CRM sync.
How Liverpool Biotech companies work and how to sell to them
What they do
Liverpool biotech companies typically monetise scientific capability before they reach fully packaged products. Revenue may come from paid feasibility work, assay development, contract research, per-sample testing, reagent or research-tool sales, licence options, milestone payments and, later, royalties on intellectual property. Some remain service-heavy, using specialist wet-lab methods to generate cash while validating a therapeutic, diagnostic or platform claim. Others sell access to a method, biological model or validated workflow that becomes embedded in a partner’s development process. Pricing is usually tied to project scope, sample volume, exclusivity and validation burden, so a small pilot can sit alongside a much longer collaboration or licence negotiation.
Who they sell to
Most Liverpool biotech suppliers sell through a technical committee rather than a single buyer. Pharmaceutical R&D teams, hospital research groups, university laboratories, contract-research organisations and public-sector research programmes tend to involve scientific leads first, then quality, regulatory, legal, finance and procurement once the work looks viable. Typical entry points are collaborative pilots, sponsored research, validation studies or framework-led service contracts, followed by a broader master services agreement, option agreement or licence. Sales cycles are usually measured in evidence milestones rather than calendar neatness: sample access, ethics sign-off, method transfer, IP review and budget ownership can each pause a deal.
What they buy
Most biotech firms tend to spend on tools that protect the chain from experiment to auditable evidence. That includes laboratory information management, electronic lab notebooks, quality-management software, document control, regulatory intelligence, pharmacovigilance support where clinical exposure exists, secure cloud hosting, bioinformatics capacity and controlled data storage. Outside software, common purchases include specialist recruitment, grant-writing support, patent advice, accountancy for grant and R&D tax work, clinical-operations support, sample logistics, lab fit-out, equipment servicing, reagents and consumables. Sellers with a compliance or workflow offer usually need to show how their category fits wet-lab practice, rather than treating the buyer as a generic office customer.
Why and how to sell to them
Buying intent often appears when a biotech moves from exploratory research into external validation. Triggers include a new grant, a collaboration with a larger life-sciences buyer, preparation for an MHRA interaction, a quality-system build-out, relocation into dedicated lab space, senior hires in regulatory or commercial roles, or a licence discussion that requires cleaner evidence trails. Outbound messages tend to land better when they speak to reproducibility, audit readiness, sample integrity, IP control and the cost of repeating work. Generic productivity language is weak; a more credible angle is reducing friction between scientists, quality teams, partners and procurement without disrupting validated methods.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Liverpool
Related directories
Frequently asked questions
How many biotech companies are there in Liverpool?
What counts as a biotech company in this list?
Which are the largest biotech companies in Liverpool?
What do biotech companies in Liverpool actually do?
How does Liverpool biotech compare internationally?
How is this list built and how fresh is the data?
How big are the typical biotech companies in Liverpool?
Are these mostly new or established biotech companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 29 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.